Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03373877
Title Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Samus Therapeutics, Inc.
Indications

myelofibrosis

Therapies

PU-H71 + Ruxolitinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Yale Cancer Center New Haven Connecticut 06511 United States Details
Ochsner Clinic Foundation New Orleans Louisiana 70121 United States Details
University of Michigan Ann Arbor Michigan 48109 United States Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
University of Nebraska Medical Center Omaha Nebraska 68198 United States Details
Duke University Medical Center Durham North Carolina 27710 United States Details
Cleveland Clinic - Taussig Cancer Institute Cleveland Ohio 44195 United States Details
Abramson Cancer Center - University of Pennsylvania Philadelphia Pennsylvania 19104 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Mays Cancer Center UT Health San Antonio San Antonio Texas 78229-3900 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field